Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc

This study has been completed.
Sponsor:
Information provided by:
Tata Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01352130
First received: May 9, 2011
Last updated: May 10, 2011
Last verified: May 2011
  Purpose

Postoperative nausea and vomiting [PONV] are common and distressing symptoms after surgery performed under general anaesthesia. 5HT3 antagonists are routinely used for prevention as well as treatment of PONV. After IRB approval we compared the effects of ondansetron and granisetron on the various intervals on ECG in 70 patients undergoing elective surgery for carcinoma breast after written informed consent. The demographic data was collected. The administration of the anaesthetic was left to the discretion of the operating room staff specialist. In the Postoperative Recovery Room patients were randomised to receive 8 mgs of ondansetron or 1 mg of granisetron intravenously. Serial ECGs were recorded at 0 mins (before injection of study drug), 2 mins, 5 mins, 15mins, 1 hour and 2 hours. Pulse rate, Non-invasive blood pressure and SpO2 were also recorded. T


Condition Intervention Phase
Prolonged QTc Interval
Drug: Ondansetron
Drug: Granisetron
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Comparative Electrocardiographic Effects of Intravenous Ondansetron and Granisetron in Patients Undergoing Surgery for Carcinoma Breast: A Prospective Single Blind Randomised Trial

Resource links provided by NLM:


Further study details as provided by Tata Memorial Hospital:

Primary Outcome Measures:
  • Effect of Granisetron and Ondansetron on QTc interval Prolongation at various time intervals after administration [ Time Frame: 0 mins (before injection of study drug), 2 mins, 5 mins, 15mins, 1 hour and 2 hours ] [ Designated as safety issue: Yes ]
    Both drugs are known to prolong QTc and other ECG intervals


Enrollment: 70
Study Start Date: March 2007
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ondansetron
Patients given Ondansetron
Drug: Ondansetron
Intravenous Ondansetron 8 mgs
Other Name: 5HT3 antagonists
Active Comparator: Granisetron
Patients given Granisetron
Drug: Granisetron
Intravenous Granisetron 1 mgs
Other Name: 5HT3 antagonists

Detailed Description:

This prospective, randomized, single blind study was conducted after our Institutional Review Board approved the study protocol, consent form and the randomization form. 70 consecutive ASA I-III patients (age18 to 60 years) undergoing breast surgery for carcinoma breast were included in the study after obtaining written informed consent. Patients refusing consent, with prolonged QTc interval, with arrhythmias or conduction defects and those with abnormal serum levels of potassium, calcium, magnesium were excluded. There was no standardized anaesthesia technique. The technique of induction of anaesthesia, maintenance and reversal of anaesthesia was left to the discretion of the staff anaesthetist in the operating theatre. The data on comorbidities, preoperative medications for the comorbidities, premedication, induction agents, analgesics, muscle relaxants and inhalation agents was collected.

Sample size calculation: A sample size calculation was performed [according to mean changes (difference of means) in QTc interval] to find out the number of patients needed to find a significant difference between the two drugs. To detect a QTc change from baseline of greater than 5 ms with α and β error of 0.05 and 0.20, respectively, and assuming an SD of QTc change of 10 ms using a one-sided test, a minimum of 35 subjects were needed in each antiemetic group.

Randomization: The patients (n= 70) were divided randomly in two groups by computer generated random numbers by the statisticians in the Clinical Research Secretariat (CRS) in our institute. Block randomization was done with blocks of 10, to allow stratification of the patients depending on whether they had received anthracycline based neoadjuvant chemotherapy. The list of randomization numbers and clinical details were maintained in the CRS.

Intervention: Once the patients arrived postoperatively in the recovery room, one of the investigators called the Clinical Research Secretariat (CRS) on phone, after completing the randomization form and gave the patient details. The Statistician allocated the drug the patient should receive which was prepared by the investigator which was either ondansetron 8 mg (Group O) or granisetron 1mg (Group G). A baseline 12 lead electrocardiogram was obtained before the drug was administered. After baseline ECG, patients in Group O were given intravenous 8 mg ondansetron and patients in group G were given 1 mg granisetron over 30 seconds. Subsequently serial 12 lead ECGs were done at 2 mins, 5 mins, 15mins, 1 hour and 2 hours. Pulse, blood pressure and SpO2 were also monitored at those intervals. Unfiltered Electrocardiograms were recorded at paper speed of 25mm/sec and at normal amplitude with a HP Vigilent Pagewriter 100TM device which automatically calculates and prints the heart rate and the duration of various ECG intervals. The investigators independently read and analyzed the ECG to confirm that the intervals obtained with the ECG machine were indeed accurate. QT and R-R intervals were measured for calculation of corrected QT (QTc) interval. The corrected QT (QTc) interval was calculated by using the formula described by Bezzet. [QTc = QT interval/√ (RR interval)]

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients undergoing breast surgery for carcinoma breast.
  • Patients between ages 18 to 60 years.
  • ASA I \ II \ III
  • Patients weight between 40 and 70 kilograms.

Exclusion Criteria:

  • Patient refusing consent
  • Prophylactic anti emetic drug administration during intraoperative period
  • Known case of prolonged QTc interval
  • Known case decompensated cardiomyopathy
  • Known case of cardiac arrhythmia or bundle branch block
  • Case of congestive heart failure with left ventricular ejection fraction <40%
  • Abnormal serum level of potassium, calcium, magnesium
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01352130

Locations
India
Tata Memorial Hopsital
Mumbai, Maharashtra, India, 400012
Sponsors and Collaborators
Tata Memorial Hospital
Investigators
Principal Investigator: Atul P Kulkarni, MD Anaes Professor
  More Information

No publications provided

Responsible Party: Dr Atul P Kulkarni, Tata Memorial Hospital
ClinicalTrials.gov Identifier: NCT01352130     History of Changes
Other Study ID Numbers: Akulkarni1
Study First Received: May 9, 2011
Last Updated: May 10, 2011
Health Authority: India: Institutional Review Board

Keywords provided by Tata Memorial Hospital:
Postoperative nausea and vomiting
Ondansetron
Granisetron
QTc interval

Additional relevant MeSH terms:
Ondansetron
Granisetron
Serotonin 5-HT3 Receptor Antagonists
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents
Antipruritics
Dermatologic Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Anti-Anxiety Agents

ClinicalTrials.gov processed this record on September 14, 2014